Synergistic Induction of Apoptosis by the Combination of TRAIL and Chemotherapy in Chemoresistant Ovarian Cancer Cells
- 1 June 2001
- journal article
- Published by Elsevier in Gynecologic Oncology
- Vol. 81 (3), 380-390
- https://doi.org/10.1006/gyno.2001.6194
Abstract
No abstract availableKeywords
This publication has 48 references indexed in Scilit:
- Mechanisms of drug resistance in ovarian cancerCancer, 2010
- Mechanisms of ApoptosisThe American Journal of Pathology, 2000
- Spontaneous development of drug resistance: mismatch repair and p53 defects in resistance to cisplatin in human tumor cellsOncogene, 2000
- p21WAF1/CIP1 Inhibits Initiator Caspase Cleavage by TRAIL Death Receptor DR4Biochemical and Biophysical Research Communications, 2000
- Adenovirus-Mediated p53 Growth Inhibition of Ovarian Cancer Cells Is Independent of Endogenous p53 StatusGynecologic Oncology, 1999
- Locoregional Apo2L/TRAIL Eradicates Intracranial Human Malignant Glioma Xenografts in Athymic Mice in the Absence of NeurotoxicityBiochemical and Biophysical Research Communications, 1999
- Cancer statistics, 1999CA: A Cancer Journal for Clinicians, 1999
- Multiple Drug Resistance Parameter Expression in Ovarian CancerGynecologic Oncology, 1998
- The caspase family of cysteine proteasesBritish Medical Bulletin, 1997
- Computerized Quantitation of Synergism and Antagonism of Taxol, Topotecan, and Cisplatin Against Human Teratocarcinoma Cell Growth: a Rational Approach to Clinical Protocol DesignJNCI Journal of the National Cancer Institute, 1994